NASDAQ:MRUSMerus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has decreased by 5.4% and is now trading at $13.75.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020.
View our earnings forecast for Merus.

Merus NV (NASDAQ:MRUS) issued its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.14. The biotechnology company had revenue of $6.30 million for the quarter, compared to analysts' expectations of $8.05 million. Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%.
View Merus' earnings history.

3 analysts have issued twelve-month target prices for Merus' shares. Their forecasts range from $16.00 to $23.00. On average, they anticipate Merus' stock price to reach $20.67 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for Merus.

News articles about MRUS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merus earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Merus.

Merus saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 288,300 shares, an increase of 14.1% from the June 15th total of 252,600 shares. Based on an average daily trading volume, of 164,600 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.5% of the company's shares are sold short.
View Merus' Current Options Chain.

Some companies that are related to Merus include IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Akebia Therapeutics (AKBA), Epizyme (EPZM), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA), Amneal Pharmaceuticals (AMRX), Innoviva (INVA) and Revance Therapeutics (RVNC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $13.75.

Merus has a market capitalization of $399.30 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

The official website for Merus is www.merus.nl.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]